종설 : 새로운 골다공증 치료제

Bisphosphonates are widely used, though gastrointestinal tolerance is a problem on daily administration. Intermittent regimen, from once weekly to once yearly, is now available in overseas and can overcome GI adverse events. New generation of anti-resorptive agents (anti-RANKL antibody and a new SERM, bazedoxifene) are promising and will be soon available for the treatment of osteoporosis. Anabolic agents such as teriparatide and strontium ranelate have marked effects on BMD and reduction on fracture risk. While none of these options is suitable for everyone, the range of future available therapies does mean that most patients can find an intervention that is effective and acceptable. Now I introduce new antiresorptive drugs (Denosumab, Integrin inhibitor, Cathepsin K inhibitor) and new bone formation drugs (PTH-Teriparatide, Strontium Ranelate, Antisclerostin Ab-Sclerostin inhibitor, 2MD, Other Wnt-signaling related drugs).